Pharmaron Beijing Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 4.17%

Pharmaron Beijing Co Ltd (300759) has an Asset Resilience Ratio of 4.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 300759 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥1.08 Billion
≈ $157.33 Million USD Cash + Short-term Investments

Total Assets

CN¥25.80 Billion
≈ $3.78 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Pharmaron Beijing Co Ltd's Asset Resilience Ratio has changed over time. See Pharmaron Beijing Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Pharmaron Beijing Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pharmaron Beijing Co Ltd (300759) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.08 Billion 4.17%
Total Liquid Assets CN¥1.08 Billion 4.17%

Asset Resilience Insights

  • Limited Liquidity: Pharmaron Beijing Co Ltd maintains only 4.17% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Pharmaron Beijing Co Ltd Industry Peers by Asset Resilience Ratio

Compare Pharmaron Beijing Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
Biotechnology 2.21%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Bachem Holding AG
SW:BANB
Biotechnology 0.00%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
ABL Bio Inc
KQ:298380
Biotechnology 1.05%
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Biotechnology 80.13%
Ascletis Pharma Inc
F:2VJ
Biotechnology 22.13%
ABCELLERA BIOLOGICS
F:8QQ
Biotechnology 29.87%

Annual Asset Resilience Ratio for Pharmaron Beijing Co Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Pharmaron Beijing Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.66% CN¥1.12 Billion
≈ $163.20 Million
CN¥23.93 Billion
≈ $3.50 Billion
+2.42pp
2023-12-31 2.24% CN¥594.33 Million
≈ $86.97 Million
CN¥26.48 Billion
≈ $3.87 Billion
-1.39pp
2022-12-31 3.64% CN¥745.36 Million
≈ $109.07 Million
CN¥20.49 Billion
≈ $3.00 Billion
-4.82pp
2021-12-31 8.45% CN¥1.55 Billion
≈ $227.49 Million
CN¥18.39 Billion
≈ $2.69 Billion
+0.81pp
2020-12-31 7.64% CN¥910.01 Million
≈ $133.16 Million
CN¥11.91 Billion
≈ $1.74 Billion
+5.79pp
2019-12-31 1.85% CN¥183.45 Million
≈ $26.84 Million
CN¥9.94 Billion
≈ $1.45 Billion
+1.84pp
2018-12-31 0.01% CN¥412.62K
≈ $60.38K
CN¥4.63 Billion
≈ $676.85 Million
--
pp = percentage points

About Pharmaron Beijing Co Ltd

SHE:300759 China Biotechnology
Market Cap
$5.08 Billion
CN¥34.69 Billion CNY
Market Cap Rank
#3564 Global
#532 in China
Share Price
CN¥23.49
Change (1 day)
-2.29%
52-Week Range
CN¥23.09 - CN¥35.90
All Time High
CN¥10080.27
About

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more